Clinical Trial: Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07038863) titled 'Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France' on March 13.

Brief Summary: In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, specific therapies are available to reduce...